Research programme: cardiometabolic disease therapeutics- Moonwalk Biosciences
Alternative Names: cardiometabolic disease theraputics - Moonwalk Biosciences; MWn - Moonwalk Biosciences; siRNA therapeutics - Moonwalk BiosciencesLatest Information Update: 05 Aug 2026
At a glance
- Originator Moonwalk Biosciences
- Class Cardiovascular therapies; Obesity therapies; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cardiovascular disorders; Metabolic disorders; Obesity
Most Recent Events
- 05 Jun 2026 Preclinical trials in Obesity in USA (Parenteral) prior to June 2026 (Moonwalk Biosciences pipeline, June 2026)
- 20 Aug 2024 Preclinical trials in Cardiovascular disorders in USA (unspecified route), before August 2024
- 20 Aug 2024 Preclinical trials in Metabolic disorders in USA (unspecified route), before August 2024